- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Adagene Inc (ADAG)
Adagene Inc stock price live, this page displays NASDAQ ADAG stock exchange data. View the ADAG premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Adagene Inc real time stock price chart below.
What Is the Adagene Inc Stock Price Today?
The Adagene Inc stock price today is 3.200.
What Is the Stock Symbol for Adagene Inc?
The stock symbol for Adagene Inc is "ADAG."
What Stock Exchange Does Adagene Inc Trade On?
Adagene Inc is listed and trades on the NASDAQ stock exchange.
Is Adagene Inc a Good Stock to Buy?
Determining whether Adagene Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADAG quote. (ISIN: US0053291078)
What Is the Adagene Inc Stock Price Today?
The Adagene Inc stock price today is 3.200.
What Is the Stock Symbol for Adagene Inc?
The stock symbol for Adagene Inc is "ADAG."
What Stock Exchange Does Adagene Inc Trade On?
Adagene Inc is listed and trades on the NASDAQ stock exchange.
Is Adagene Inc a Good Stock to Buy?
Determining whether Adagene Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADAG quote. (ISIN: US0053291078)
Fair Value
An estimate of a Adagene's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.170
3.592
52 wk Range
1.300
4.850
ADAG is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Adagene's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.1703.592
52 wk Range
1.3004.850
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ADAG Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Adagene's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
10.742
Upside
+235.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Form 13D/A Adagene For: 8 June- Investing.com
- Form 13D/A Adagene For: 8 June
- Investing.com
Form 13G ADAGENE INC. For: 7 May- Investing.com
Form 6K Adagene Inc For: 17 April- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 10.742
(+235.68% Upside)
Earnings
Latest Release
Jun 03, 2026
EPS / Forecast
-0.10 / -0.25
Revenue / Forecast
-- / --
Compare ADAG to Peers and Sector
Metrics to compare | ADAG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADAGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.0x | −5.9x | −0.4x | |
PEG Ratio | −0.24 | −0.12 | 0.00 | |
Price/Book | 6.0x | 1.8x | 2.6x | |
Price / LTM Sales | 27.6x | 16.2x | 3.0x | |
Upside (Analyst Target) | 181.3% | 126.6% | 57.2% | |
Fair Value Upside | Unlock | 7.0% | 9.6% | Unlock |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Adagene (ADAG) Stock Price Today?
The Adagene stock price today is 3.200 USD.
What Stock Exchange Does Adagene Trade On?
Adagene is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Adagene?
The stock symbol for Adagene is "ADAG."
What Is the Adagene (ADAG) Afterhours Price Today? (Afterhours variable test: 3.170) Current Date: Jul 25, 2026
After hours price: 3.170. After hours price change (units): -0.030. Price change percentage: -0.940%
What Is the Adagene Market Cap?
As of today, Adagene market cap is 222.660M USD.
What Is Adagene's Earnings Per Share (TTM)?
The Adagene EPS (TTM) is -0.375.
When Is the Next Adagene Earnings Date?
Adagene will release its next earnings report on Sep 02, 2026.
From a Technical Analysis Perspective, Is ADAG a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Adagene Stock Split?
Adagene has split 0 times.
How Many Employees Does Adagene Have?
Adagene has 128 employees.
What is the current trading status of Adagene (ADAG)?
As of Jul 25, 2026, Adagene (ADAG) is trading at a price of 3.200 USD, with a previous close of 3.370 USD. The stock has fluctuated within a day range of 3.170 USD to 3.592 USD, while its 52-week range spans from 1.300 USD to 4.850 USD.
What Is Adagene (ADAG) Price Target According to Analysts?
The average 12-month price target for Adagene is 10.742 USD, with a high estimate of 17.45 USD and a low estimate of 7 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +235.68% Upside potential.
What Is the ADAG After Hours Price?
ADAG's last after hours stock price is 3.170 USD, the stock has decreased by -0.030, or -0.940%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.